Investing in Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)
On Friday, January 21, Arrowhead Pharmaceuticals Inc. saw a price drop of 3.18%, with the stock closing at $50.84. The previous day's closing price was $52.51, and the stock fluctuated between $50.82 and $53.49 during the trading session. Its 5-year monthly beta is 1.23.
Stock Performance Overview
In the last year, Arrowhead's 52-week high and low were $93.66 and $52.35, respectively, reflecting a 27.48% decline over the last month.
Investment Insights
Renowned investor Warren Buffett advocates buying valuable assets when they are inexpensive. This strategy is applicable to small-cap stocks with significant growth potential.
Arrowhead Pharmaceuticals has a market cap of approximately $5.29 billion, with earnings per share (EPS) projected at -$0.45 for the upcoming quarter (Feb 02, 2022 - Feb 07, 2022). EPS growth is expected to reach -$1.29 for FY 2022 and -$1.54 for FY 2023, with a projected growth rate of 5.10% for 2022 and -19.40% for 2023.
Analyst Ratings
According to 11 analysts, Arrowhead Pharmaceuticals holds an average rating of "Buy" based on a scale from 1.00 (strong buy) to 5.00 (strong sell). Currently, 2 analysts rate it as a "Hold," while 9 recommend it as a "Buy." There are no ratings for "Overweight," "Underweight," or "Sell."
Technical Indicators
ARWR is currently about 18.11% and 24.21% below the 20-day and 50-day simple moving averages, respectively. The Relative Strength Index (RSI) is at 27.07, with a 7-day volatility ratio of 5.41% and 5.36% over 30 days. Analysts have set a 52-week price target of $86.64, with a low of $45.00 and a high of $106.00.
Comparative Analysis
Comparing Arrowhead to its peers reveals weaker performance. For instance, Ionis Pharmaceuticals has seen a -0.43% change today and -51.61% over the last year, while Johnson & Johnson is down -0.23% today, but remains 0.81% above its price from a year ago.
Market Activity
Over the past few days, Arrowhead's trading volume averaged 0.6 million shares, with a total of 104.27 million shares outstanding. Insiders own 5.20% of the shares, while institutional holders own 65.40%.
Conclusion
With a current YTD price change of -23.32%, there remains potential for growth. Investor optimism could see an increase in the stock as the next quarter approaches.
